Shares of Lupin Ltd dropped 2.8% despite a significant Q3 profit increase of 38.8% year-on-year. The company's revenue surged 102.7%, reaching Rs 57,677 crore. Lupin received USFDA approval for a new nasal spray, and plans to transfer its OTC healthcare business to a new subsidiary. Mixed analyst sentiment suggests potential upside.
